Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Sinobiomed: Negative Financials; Vibrant Development Program

publication date: Aug 21, 2008
View a Printer Friendly version of this page, allowing you to print the page.

Sinobiomed has issued a number of press releases in recent days, each detailing the company’s progress in developing a new drug. But its financial reports are harder to find. You can’t really blame them: the company’s financial situation is dismal, so who would want to talk about that? Sinobiomed’s hope is that one of its products in development will turn its fortunes around sometime in the very near future. Meanwhile, the company is scraping along, depending on short-term financial patches to keep bankruptcy at bay. More details...

Stock Symbol: (OTCBB: SOBM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China